SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wierda, W. G. Articles by Kipps, T. J. Search for Related Content PubMed PubMed Citation Articles by Wierda, W. G. Articles by Kipps, T. J. Related Collections Neoplasia Plenary Papers Clinical Trials and Observations Gene Therapy Related Letter in Blood Online Social Bookmarking                   What's this? Next Article  Blood, 1 November 2000, Vol. 96, No. 9, pp. 2917-2924 PLENARY PAPER CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia William G. Wierda, Mark J. Cantwell, Sandra J. Woods, Laura Z. Rassenti, Charles E. Prussak, and Thomas J. Kipps From the Division of Hematology/Oncology, Department of Medicine, and the UCSD Human Gene Therapy Program, University of California-San Diego, La Jolla, CA; Immunogenex, Inc, La Jolla, CA; and Molecular Medicine/LLC, UCSD, La Jolla, CA. Chronic lymphocytic leukemia (CLL) cells can be made to express recombinant CD40-ligand (CD154) by transduction with a replication-defective adenovirus vector (Ad-CD154). Ad-CD154-transduced and bystander leukemia cells become highly effective antigen-presenting cells that can induce CLL-specific autologous cytotoxic T lymphocytes in vitro. This study investigated the immunologic and clinical responses to infusion of autologous Ad-CD154-CLL cells in patients with CLL. After a one-time bolus infusion of autologous Ad-CD154-transduced leukemia cells, there was increased or de novo expression of immune accessory molecules on bystander, noninfected CLL cells in vivo. Treated patients also developed high plasma levels of interleukin-12 and interferon-, the magnitudes of which corresponded to absolute blood CD4+ T-cell counts before therapy. On average, patients experienced a greater than 240% increase in absolute blood T-cell counts within 1 to 4 weeks of treatment. Moreover, treatment increased the numbers of leukemia-specific T cells, demonstrated by autologous ELISPOT assay and mixed lymphocyte reactions. These biologic effects were associated with reductions in leukemia cell counts and lymph node size. Treatment did not induce autoimmune thrombocytopenia or hemolytic anemia and no dose-limiting toxicity was observed. This approach may provide a novel and effective form of gene therapy for patients with this disease. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia Gabriele Anether, Ingrid Marschitz, Inge Tinhofer, and Richard Greil Blood 2002 99: 722-723. [Full Text] [PDF] This article has been cited by other articles: J. A. Burger, P. Ghia, A. Rosenwald, and F. Caligaris-Cappio The microenvironment in mature B-cell malignancies: a target for new treatment strategies Blood, October 15, 2009; 114(16): 3367 - 3375. [Abstract] [Full Text] [PDF] C. Frecha, C. Costa, C. Levy, D. Negre, S. J. Russell, A. Maisner, G. Salles, K.-W. Peng, F.-L. Cosset, and E. Verhoeyen Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors Blood, October 8, 2009; 114(15): 3173 - 3180. [Abstract] [Full Text] [PDF] Q.-L. Wu, I. N. Buhtoiarov, P. M. Sondel, A. L. Rakhmilevich, and E. A. Ranheim Tumoricidal Effects of Activated Macrophages in a Mouse Model of Chronic Lymphocytic Leukemia J. Immunol., June 1, 2009; 182(11): 6771 - 6778. [Abstract] [Full Text] [PDF] T. J. Kipps Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy ASCO Educational Book, January 1, 2009; 2009(1): 385 - 393. [Abstract] [Full Text] [PDF] S Serba, J Schmidt, N Wentzensen, E Ryschich, and A Marten Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma Gut, March 1, 2008; 57(3): 344 - 351. [Abstract] [Full Text] [PDF] T. Fukuda, L. Chen, T. Endo, L. Tang, D. Lu, J. E. Castro, G. F. Widhopf II, L. Z. Rassenti, M. J. Cantwell, C. E. Prussak, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a PNAS, February 26, 2008; 105(8): 3047 - 3052. [Abstract] [Full Text] [PDF] W. G. Wierda Treatments for Patients with Chronic Lymphocytic Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 297 - 305. [Abstract] [Full Text] [PDF] A. P. Kater, M. H. J. van Oers, and T. J. Kipps Cellular immune therapy for chronic lymphocytic leukemia Blood, October 15, 2007; 110(8): 2811 - 2818. [Abstract] [Full Text] [PDF] A. Liu, A. Guardino, L. Chinsangaram, M. J. Goldstein, D. Panicali, and R. Levy Therapeutic Vaccination against Murine Lymphoma by Intratumoral Injection of Recombinant Fowlpox Virus Encoding CD40 Ligand Cancer Res., July 15, 2007; 67(14): 7037 - 7044. [Abstract] [Full Text] [PDF] R. H. Vonderheide Prospect of Targeting the CD40 Pathway for Cancer Therapy Clin. Cancer Res., February 15, 2007; 13(4): 1083 - 1088. [Abstract] [Full Text] [PDF] S. S. Neelapu and L. W. Kwak Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies Hematology, January 1, 2007; 2007(1): 243 - 249. [Abstract] [Full Text] [PDF] J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, et al. T lymphocytes redirected against the {kappa} light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells Blood, December 1, 2006; 108(12): 3890 - 3897. [Abstract] [Full Text] [PDF] F. Dicker, A. P. Kater, C. E. Prada, T. Fukuda, J. E. Castro, G. Sun, J. Y. Wang, and T. J. Kipps CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53 Blood, November 15, 2006; 108(10): 3450 - 3457. [Abstract] [Full Text] [PDF] D. de Totero, R. Meazza, S. Zupo, G. Cutrona, S. Matis, M. Colombo, E. Balleari, I. Pierri, M. Fabbi, M. Capaia, et al. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells Blood, May 1, 2006; 107(9): 3708 - 3715. [Abstract] [Full Text] [PDF] R. F. Rousseau, E. Biagi, A. Dutour, E. S. Yvon, M. P. Brown, T. Lin, Z. Mei, B. Grilley, E. Popek, H. E. Heslop, et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation Blood, February 15, 2006; 107(4): 1332 - 1341. [Abstract] [Full Text] [PDF] W. G. Wierda Current and Investigational Therapies for Patients with CLL Hematology, January 1, 2006; 2006(1): 285 - 294. [Abstract] [Full Text] [PDF] J. C. Fratantoni, L. Li, L. N. Liu, M. V. Peshwa, M. Brenner, E. Yvon, G. Carrum, and E. Biagi A Practical Approach for Achieving Clinical Immunotherapy of CLL with hCD40L- and hIL-2-Expressing Autologous Tumor Cells. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 450 - 450. [Abstract] C. Palena, K. A. Foon, D. Panicali, A. G. Yafal, J. Chinsangaram, J. W. Hodge, J. Schlom, and K. Y. Tsang Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules Blood, November 15, 2005; 106(10): 3515 - 3523. [Abstract] [Full Text] [PDF] C. Mayr, D. M. Kofler, H. Buning, D. Bund, M. Hallek, and C.-M. Wendtner Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells Blood, November 1, 2005; 106(9): 3223 - 3226. [Abstract] [Full Text] [PDF] E. Biagi, R. Rousseau, E. Yvon, M. Schwartz, G. Dotti, A. Foster, D. Havlik-Cooper, B. Grilley, A. Gee, K. Baker, et al. Responses to Human CD40 Ligand/Human Interleukin-2 Autologous Cell Vaccine in Patients with B-Cell Chronic Lymphocytic Leukemia Clin. Cancer Res., October 1, 2005; 11(19): 6916 - 6923. [Abstract] [Full Text] [PDF] W. G. Wierda, T. J. Kipps, and M. J. Keating Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6325 - 6332. [Abstract] [Full Text] [PDF] A. P. Kater, F. Dicker, M. Mangiola, K. Welsh, R. Houghten, J. Ostresh, A. Nefzi, J. C. Reed, C. Pinilla, and T. J. Kipps Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis Blood, September 1, 2005; 106(5): 1742 - 1748. [Abstract] [Full Text] [PDF] F. Dicker, A. P. Kater, T. Fukuda, and T. J. Kipps Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells Blood, April 15, 2005; 105(8): 3193 - 3198. [Abstract] [Full Text] [PDF] E. Biagi, G. Dotti, E. Yvon, E. Lee, M. Pule, S. Vigouroux, S. Gottschalk, U. Popat, R. Rousseau, and M. Brenner Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes Blood, March 15, 2005; 105(6): 2436 - 2442. [Abstract] [Full Text] [PDF] M. Bonyhadi, M. Frohlich, A. Rasmussen, C. Ferrand, L. Grosmaire, E. Robinet, J. Leis, R. T. Maziarz, P. Tiberghien, and R. J. Berenson In Vitro Engagement of CD3 and CD28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia J. Immunol., February 15, 2005; 174(4): 2366 - 2375. [Abstract] [Full Text] [PDF] S. C. Hill, S. J. Youde, S. Man, G. R. Teale, A. J. Baxendale, A. Hislop, C. C. Davies, D. M. Luesley, A. M. Blom, A. B. Rickinson, et al. Activation of CD40 in Cervical Carcinoma Cells Facilitates CTL Responses and Augments Chemotherapy-Induced Apoptosis J. Immunol., January 1, 2005; 174(1): 41 - 50. [Abstract] [Full Text] [PDF] M. Hallek and On Behalf Of The German CLL Study Group Chronic Lymphocytic Leukemia (CLL): First-Line Treatment Hematology, January 1, 2005; 2005(1): 285 - 291. [Abstract] [Full Text] [PDF] C. S. Gricks, D. Zahrieh, A. J. Zauls, G. Gorgun, D. Drandi, K. Mauerer, D. Neuberg, and J. G. Gribben Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells Blood, December 15, 2004; 104(13): 4002 - 4009. [Abstract] [Full Text] [PDF] D. Watson, G. Y. Zhang, M. Sartor, and S. I. Alexander "Pruning" of Alloreactive CD4+ T Cells Using 5- (and 6-)Carboxyfluorescein Diacetate Succinimidyl Ester Prolongs Skin Allograft Survival J. Immunol., December 1, 2004; 173(11): 6574 - 6582. [Abstract] [Full Text] [PDF] C.-H. Lin, T. Kerkau, C. Guntermann, M. Trischler, N. Beyersdorf, Y. Scheuring, H.-P. Tony, C. Kneitz, M. Wilhelm, P. Mueller, et al. Superagonistic Anti-CD28 Antibody TGN1412 as a Potential Immunotherapeutic for the Treatment of B Cell Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2519 - 2519. [Abstract] M. von Bergwelt-Baildon, B. Maecker, J. Schultze, and J. G. Gribben CD40 activation: potential for specific immunotherapy in B-CLL Ann. Onc., June 1, 2004; 15(6): 853 - 857. [Abstract] [Full Text] [PDF] M. A. Caligiuri, A. Velardi, D. A. Scheinberg, and I. M. Borrello Immunotherapeutic Approaches for Hematologic Malignancies Hematology, January 1, 2004; 2004(1): 337 - 353. [Abstract] [Full Text] [PDF] A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF] R. Greil, G. Anether, K. Johrer, and I. Tinhofer Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330. [Abstract] [Full Text] [PDF] R. Rieger and T. J. Kipps CpG Oligodeoxynucleotides Enhance the Capacity of Adenovirus-mediated CD154 Gene Transfer to Generate Effective B-Cell Lymphoma Vaccines Cancer Res., July 15, 2003; 63(14): 4128 - 4135. [Abstract] [Full Text] [PDF] T. E. Battle, W. G. Wierda, L. Z. Rassenti, D. Zahrieh, D. Neuberg, T. J. Kipps, and D. A. Frank In Vivo Activation of Signal Transducer and Activator of Transcription 1 after CD154 Gene Therapy for Chronic Lymphocytic Leukemia Is Associated with Clinical and Immunologic Response Clin. Cancer Res., June 1, 2003; 9(6): 2166 - 2172. [Abstract] [Full Text] [PDF] E. Gitelson, C. Hammond, J. Mena, M. Lorenzo, R. Buckstein, N. L. Berinstein, K. Imrie, and D. E. Spaner Chronic Lymphocytic Leukemia-reactive T Cells during Disease Progression and after Autologous Tumor Cell Vaccines Clin. Cancer Res., May 1, 2003; 9(5): 1656 - 1665. [Abstract] [Full Text] [PDF] J. Briones, J. M. Timmerman, D. L. Panicalli, and R. Levy Antitumor Immunity After Vaccination With B Lymphoma Cells Overexpressing a Triad of Costimulatory Molecules J Natl Cancer Inst, April 2, 2003; 95(7): 548 - 555. [Abstract] [Full Text] [PDF] F. Bovia, P. Salmon, T. Matthes, K. Kvell, T. H. Nguyen, C. Werner-Favre, M. Barnet, M. Nagy, F. Leuba, J.-F. Arrighi, et al. Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors Blood, March 1, 2003; 101(5): 1727 - 1733. [Abstract] [Full Text] [PDF] L. Granziero, P. Circosta, C. Scielzo, E. Frisaldi, S. Stella, M. Geuna, S. Giordano, P. Ghia, and F. Caligaris-Cappio CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes Blood, March 1, 2003; 101(5): 1962 - 1969. [Abstract] [Full Text] [PDF] J. Linderoth, M. Jerkeman, E. Cavallin-Stahl, S. Kvaloy, and E. Torlakovic Immunohistochemical Expression of CD23 and CD40 May Identify Prognostically Favorable Subgroups of Diffuse Large B-cell Lymphoma: A Nordic Lymphoma Group Study Clin. Cancer Res., February 1, 2003; 9(2): 722 - 728. [Abstract] [Full Text] [PDF] M.-R. Rezvany, M. Jeddi-Tehrani, H. Wigzell, A. Osterborg, and H. Mellstedt Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia Blood, February 1, 2003; 101(3): 1063 - 1070. [Abstract] [Full Text] [PDF] M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps Biology and Treatment of Chronic Lymphocytic Leukemia Hematology, January 1, 2003; 2003(1): 153 - 175. [Abstract] [Full Text] [PDF] C.-M. Wendtner, D. M. Kofler, H. D. Theiss, C. Kurzeder, R. Buhmann, C. Schweighofer, L. Perabo, S. Danhauser-Riedl, J. Baumert, W. Hiddemann, et al. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors Blood, August 13, 2002; 100(5): 1655 - 1661. [Abstract] [Full Text] [PDF] J. Briones, J. Timmerman, and R. Levy In Vivo Antitumor Effect of CD40L-transduced Tumor Cells as a Vaccine for B-Cell Lymphoma Cancer Res., June 1, 2002; 62(11): 3195 - 3199. [Abstract] [Full Text] [PDF] P. Chu, D. Deforce, I. M. Pedersen, Y. Kim, S. Kitada, J. C. Reed, and T. J. Kipps Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia PNAS, March 19, 2002; 99(6): 3854 - 3859. [Abstract] [Full Text] [PDF] G. Anether, I. Marschitz, I. Tinhofer, and R. Greil Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia Blood, January 15, 2002; 99(2): 722 - 723. [Full Text] [PDF] K. Kato, Y. Takaue, and H. Wakasugi T-cell-conditioned medium efficiently induces the maturation and function of human dendritic cells J. Leukoc. Biol., December 1, 2001; 70(6): 941 - 949. [Abstract] [Full Text] [PDF] M. Gorschluter, C. Ziske, A. Glasmacher, and I. G. H. Schmidt-Wolf Current Clinical and Laboratory Strategies to Augment the Efficacy of Immunotherapy in Multiple Myeloma Clin. Cancer Res., August 1, 2001; 7(8): 2195 - 2204. [Abstract] [Full Text] [PDF] R. H. Vonderheide, J. P. Dutcher, J. E. Anderson, S. G. Eckhardt, K. F. Stephans, B. Razvillas, S. Garl, M. D. Butine, V. P. Perry, R. J. Armitage, et al. Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients J. Clin. Oncol., July 1, 2001; 19(13): 3280 - 3287. [Abstract] [Full Text] [PDF]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020